FMP
Vaxcyte, Inc.
PCVX
NASDAQ
Vaxcyte, Inc., a clinical-stage biotechnology vaccine company, develops novel protein vaccines to prevent or treat bacterial infectious diseases. Its lead vaccine candidate is VAX-24, a 24-valent investigational pneumococcal conjugate vaccine that is in Phase 1/2 clinical trials to treat invasive pneumococcal disease and pneumonia. The company also develops VAX-XP to protect against emerging strains and address antibiotic resistance; VAX-A1, a conjugate vaccine candidate designed to treat Group A Strep; and VAX-PG, a novel protein vaccine candidate targeting keystone pathogen responsible for periodontitis. The company was formerly known as SutroVax, Inc. and changed its name to Vaxcyte, Inc. in May 2020. Vaxcyte, Inc. was incorporated in 2013 and is headquartered in San Carlos, California.
74.37 USD
1.35 (1.82%)
2024 Q4
2024 Q3
2024 Q2
2024 Q1
0
0
0
0
0
4.5M
3.48M
3.09M
0
-4.5M
-3.48M
-3.09M
162.17M
139.92M
149.5M
114.35M
133.61M
116.94M
131.51M
94.59M
28.55M
22.99M
18M
19.89M
0
0
-3.48M
0
28.55M
22.99M
21.47M
19.89M
0
0
-394k
0
-162.17M
-139.92M
-152.98M
-114.47M
25.09M
36.8M
24.28M
19.45M
-137.08M
-103.12M
-128.7M
-95.02M
0
0
0
-19.33M
-137.08M
-103.12M
-128.7M
-95.02M
-1.12
-0.83
-1.1
-0.85
-1.12
-0.83
-1.1
-0.85
122.85M
123.69M
117.26M
111.69M
122.85M
123.69M
117.26M
111.69M
-52.58M
-139.92M
-152.98M
-113.47M
2024 Q4
2024 Q3
2024 Q2
2024 Q1
-1.25B
-1.15B
-1.02B
-924.39M
-137.08M
-103.12M
-128.7M
-95.02M
0
5.53M
0
0
0
0
0
0
-1.39B
-1.25B
-1.15B
-1.02B
-137.08M
-97.6M
-128.7M
-95.02M
2024 Q4
2024 Q3
2024 Q2
2024 Q1
332.62M
249.93M
152.75M
157.31M
4.79M
0
3.48M
3.09M
-30.03M
-38.08M
-45.37M
-12.07M
357.87M
288.01M
194.65M
166.3M
2024 Q4
2024 Q3
2024 Q2
2024 Q1
0
0
0
0
0
0
0
0
0
0
0
0
All figures are in USD.